Hemifacial spasm and reinnervation synkinesias: long-term treatment with either Botox® or Dysport®
Botulinum toxin is considered the treatment of choice for hemifacial spasm (HFS) and reinnervation synkinesias (RS). We present 133 patients with HFS (n = 97) and RS (n = 36) who have been treated with either Botox® (n = 78) or Dysport® (n = 55) exclusively for 6 years (range 2–12 years). The Botox® dose was 21 ± 8 MU, the Dysport® dose 46 ± 22 MU. The therapeutic effect started after 7.1 ± 2.3 days and lasted for 12.5 ± 3.9 weeks. It was stable throughout the observation period in 85% of all patients. Adverse effects occurred in 5.4% of injection series. No patient terminated treatment because of unsatisfactory results. Secondary therapy failure did not occur. With an effective conversion ratio of Botox®:Dysport® = 1:2.56 there were no differences between both drugs with respect to therapeutic efficacy and adverse effects thus confirming the hypothesis that there may not be intrinsic differences between both products.
KeywordsHemifacial spasm Reinnervation sykinesias Botulinum toxin Conversion factor Botox® Dysport®
- Costa J, Espirito-Santo C, Borges A, Ferreira JJ, Coelho M, Moore P, Sampaio C (2005) Botulinum toxin type A therapy for hemifacial spasm. Cochrane Database Syst Rev 2005(1):CD004899Google Scholar
- Gomez-Perals LF, Ortega-Martinez M, Fernandez-Portales I, Cabezudo-Artero JM (2005) Hemifacial spasm as clinical presentation of intracranial meningiomas. Report of three cases and review of the literature. Neurocirugia (Astur) 16(1):21–25 discussion 26Google Scholar
- Mohammadi B, Buhr N, Bigalke H, Krampfl K, Dengler R, Kollewe K (2009a) A long-term follow-up of botulinum toxin A in cervical dystonia. Neurol Res 31(5):463–466Google Scholar
- Sampaio C, Ferreira JJ, Simoes F, Rosas MJ, Magalhaes M, Correia AP, Bastos-Lima A, Martins R, Castro-Caldas A (1997) DYSBOT: a single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A–Dysport and Botox–assuming a ratio of 4:1. Mov Disord 12(6):1013–1018CrossRefPubMedGoogle Scholar